JP2017510585A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510585A5
JP2017510585A5 JP2016558751A JP2016558751A JP2017510585A5 JP 2017510585 A5 JP2017510585 A5 JP 2017510585A5 JP 2016558751 A JP2016558751 A JP 2016558751A JP 2016558751 A JP2016558751 A JP 2016558751A JP 2017510585 A5 JP2017510585 A5 JP 2017510585A5
Authority
JP
Japan
Prior art keywords
formulation
item
lyophilized
less
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016558751A
Other languages
English (en)
Japanese (ja)
Other versions
JP7058940B2 (ja
JP2017510585A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/022141 external-priority patent/WO2015148444A1/en
Publication of JP2017510585A publication Critical patent/JP2017510585A/ja
Publication of JP2017510585A5 publication Critical patent/JP2017510585A5/ja
Priority to JP2022007013A priority Critical patent/JP7503583B2/ja
Application granted granted Critical
Publication of JP7058940B2 publication Critical patent/JP7058940B2/ja
Priority to JP2024033771A priority patent/JP7759978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016558751A 2014-03-24 2015-03-24 凍結乾燥第ｉｘ因子製剤 Active JP7058940B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022007013A JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ｉｘ因子製剤
JP2024033771A JP7759978B2 (ja) 2014-03-24 2024-03-06 凍結乾燥第ｉｘ因子製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969801P 2014-03-24 2014-03-24
US61/969,801 2014-03-24
PCT/US2015/022141 WO2015148444A1 (en) 2014-03-24 2015-03-24 Lyophilized factor ix formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2020016131A Division JP2020063313A (ja) 2014-03-24 2020-02-03 凍結乾燥第ｉｘ因子製剤
JP2022007013A Division JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ｉｘ因子製剤

Publications (3)

Publication Number Publication Date
JP2017510585A JP2017510585A (ja) 2017-04-13
JP2017510585A5 true JP2017510585A5 (https=) 2018-05-10
JP7058940B2 JP7058940B2 (ja) 2022-04-25

Family

ID=54196282

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016558751A Active JP7058940B2 (ja) 2014-03-24 2015-03-24 凍結乾燥第ｉｘ因子製剤
JP2020016131A Pending JP2020063313A (ja) 2014-03-24 2020-02-03 凍結乾燥第ｉｘ因子製剤
JP2022007013A Active JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ｉｘ因子製剤
JP2024033771A Active JP7759978B2 (ja) 2014-03-24 2024-03-06 凍結乾燥第ｉｘ因子製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020016131A Pending JP2020063313A (ja) 2014-03-24 2020-02-03 凍結乾燥第ｉｘ因子製剤
JP2022007013A Active JP7503583B2 (ja) 2014-03-24 2022-01-20 凍結乾燥第ｉｘ因子製剤
JP2024033771A Active JP7759978B2 (ja) 2014-03-24 2024-03-06 凍結乾燥第ｉｘ因子製剤

Country Status (16)

Country Link
US (3) US10772942B2 (https=)
EP (1) EP3123090A4 (https=)
JP (4) JP7058940B2 (https=)
KR (1) KR102385372B1 (https=)
AR (1) AR099838A1 (https=)
AU (3) AU2015236340B2 (https=)
CA (1) CA2943034C (https=)
CL (1) CL2016002386A1 (https=)
EA (2) EA202092926A3 (https=)
IL (3) IL247869B (https=)
MA (1) MA39779A (https=)
MX (2) MX387269B (https=)
PH (1) PH12016501877A1 (https=)
SG (3) SG10201913735SA (https=)
TW (1) TWI700101B (https=)
WO (1) WO2015148444A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014144549A1 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
MX2019006444A (es) * 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
WO2019014338A1 (en) * 2017-07-11 2019-01-17 Universal Stabilization Technologies, Inc. METHOD FOR PRESERVING BIOPHARMACEUTICAL PRODUCTS
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
BR112022015272A2 (pt) 2020-02-04 2022-09-20 Regeneron Pharma Teor de umidade residual alvo para produto de fármaco liofilizado
US20210395325A1 (en) * 2020-05-11 2021-12-23 Alkermes Pharma Ireland Limited Il-2 fusion polypeptide compositions and methods of making and using the same
CN118557531B (zh) * 2024-08-02 2024-10-18 成都蓉生药业有限责任公司 一种重组人凝血因子VIII-Fc融合蛋白冻干制剂的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2124690C (en) 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
DE4405426A1 (de) 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5770700A (en) 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
IN184589B (https=) * 1996-10-16 2000-09-09 Alza Corp
US20010031721A1 (en) 1999-05-05 2001-10-18 Chandra Webb Highly concentrated, lyophilized, and liquid factor IX formulations
JP2001151694A (ja) 1999-09-17 2001-06-05 Takeda Chem Ind Ltd タンパク質粉体の製造法
CA2383144A1 (en) 1999-09-17 2001-03-29 Takeda Chemical Industries, Ltd. Process for producing protein powder
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
WO2002040544A2 (en) 2000-11-14 2002-05-23 Board Of Regents, University Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
MXPA04001982A (es) 2001-09-04 2004-06-07 Merck Patent Gmbh Factor ix modificado.
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
PL2298347T3 (pl) 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005060378A (ja) 2003-07-28 2005-03-10 Yamanouchi Pharmaceut Co Ltd 生理活性蛋白質含有凍結乾燥製剤
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
WO2006029467A1 (en) * 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
PT2363414T (pt) 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005317166B2 (en) 2004-12-15 2009-09-10 Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
US7956160B2 (en) 2005-07-22 2011-06-07 Amgen Inc. Concentrated protein lyophilates, methods, and uses
WO2007044616A2 (en) * 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
PL1942868T5 (pl) * 2005-11-01 2023-12-27 Wyeth Llc Roztwór chlorku sodu do odtwarzania lub rozcieńczania leku
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
TWI428448B (zh) 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
EP2423307A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
US8015841B2 (en) * 2006-09-08 2011-09-13 Praxair Technology, Inc. Cryogenic refrigeration system for lyophilization
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CN102026653B (zh) 2007-10-15 2014-06-18 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ⅸ变体
BRPI0821591A2 (pt) 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
NZ603997A (en) 2007-12-27 2013-02-22 Baxter Int Chemically Modified Factor IX
JP2011517950A (ja) 2008-04-16 2011-06-23 バイエル・ヘルスケア・エルエルシー 第ｉｘ因子の部位特異的修飾
SG189790A1 (en) 2008-04-16 2013-05-31 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
US20110137011A1 (en) 2008-04-21 2011-06-09 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
DK2280734T3 (da) 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
CA2729972C (en) 2008-08-05 2018-11-20 Wyeth Llc Lyophilization above collapse
MX2011003074A (es) 2008-09-24 2011-04-19 Stabilitech Ltd Metodo para conservar polipeptidos utilizando un azucar y polietilenimina.
JP2012530721A (ja) 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
PL3552619T3 (pl) * 2010-07-09 2025-12-01 Bioverativ Therapeutics Inc. Polipeptydy czynnika ix i sposoby ich zastosowania
EP2623497B1 (en) 2010-09-30 2016-01-20 Toyama Chemical Co., Ltd. Meglumine salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
JP6125436B2 (ja) 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
WO2013185113A1 (en) * 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
HK1213521A1 (zh) * 2012-09-25 2016-07-08 Bioverativ Therapeutics Inc. Fix多肽的應用
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations

Similar Documents

Publication Publication Date Title
JP2017510585A5 (https=)
EP2373293B2 (en) Compositions with reduced dimer formation
US7879805B2 (en) High temperature stable peptide formulation
CN102869373B (zh) 不含白蛋白的肉毒杆菌毒素制剂
CN1152713C (zh) 含有海藻糖的干燥的血液因子组合物
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
JP2005526084A5 (https=)
CN110022855B (zh) 室温稳定的冻干蛋白质
CN104159614A (zh) TNF-α抗体的药物制剂
JP2012121894A (ja) Ｉｌ−１アンタゴニスト製剤
JP2009540001A5 (https=)
JP2016516722A5 (https=)
JP2010531340A (ja) 新規処方物
CN106687126B (zh) 因子viii制剂
TWI243057B (en) Formulations for protection of peg-interferon alpha conjugates
TW201605468A (zh) 長效人類生長激素接合物之製劑
JP2022171602A5 (https=)
CA2683317A1 (en) Stabilization of liquid solutions of recombinant protein for frozen storage
JP6166470B2 (ja) ゴナドトロピンのための新規製剤
JP4564652B2 (ja) ０．５ｍｌ未満の容量を投与するための凍結乾燥タンパク質組成物を含む１回量注射器
JP2022514942A (ja) ペグアスパラガーゼの凍結乾燥組成物
AU2021227095B2 (en) Daptomycin formulation
JPWO2016080367A1 (ja) 安定化されたペプチド組成物
EA026064B1 (ru) Твердая фармацевтическая композиция, полученная с помощью предварительной стадии замораживания и стадии лиофилизации
KR20230146515A (ko) 개선된 동결건조 제형